A study by researchers at Johns Hopkins University offers an emerging method to achieve off-the-shelf protein-based immunotherapeutic for treating T-cell cancers. As reported in Science Translational Medicine, researchers tested an approach to determine whether a CD3 bispecific T-cell-engaging antibodies (BsAb) could deplete T-cell malignancies while safeguarding healthy T cells. Oncology Times recently chatted with Suman Paul, MBBS, PhD, Assistant Professor of Oncology at Johns Hopkins University, to discuss their recent work and the impact of off-the-shelf immunotherapy for patients with cancer.

https://journals.lww.com/oncology-times/Fulltext/2021/10050/Advances_in_Off_the_Shelf_Immunotherapy__Expert.5.aspx